NSE · WINDLAS
Windlas Biotech Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹248 Cr with net profit ₹18 Cr — a 7.11% net margin, versus 6.72% the period before.
Shareholding
As of 2026-06-30
- Promoter63.31%
- Public24.8%
- FII2.04%
- DII9.84%
44,996 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.69× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #13 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,87,521 Cr | 84.04 | 22.29 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹48,614 Cr | 42.43 | 4.7 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹43,986 Cr | 38.76 | 9.71 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹29,630 Cr | 102.81 | 23 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹21,248 Cr | 31.94 | 6.3 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹18,800 Cr | 28.62 | 4.81 | 15.87% | 20.04% |
| Shilpa Medicare Ltd. | ₹18,383 Cr | 64.64 | 7.1 | 9.39% | 17.67% |
| Marksans Pharma Limited | ₹14,973 Cr | 28.98 | 4.95 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,448 Cr | 54.09 | 6.27 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,738 Cr | 53.32 | 7.21 | 12.36% | 18.59% |
| Windlas Biotech Limited(this company) | ₹2,331 Cr | 35.07 | 4.01 | 11.44% | 7.35% |
AI analysis
AI-generated · google/gemini-2.5-flashWindlas Biotech Limited (WINDLAS) is listed with a market capitalization of Rs 1799 Cr. The company reported revenue of Rs 921.89 Cr and a net profit margin of 7.35%.
Positives
- +Revenue grew 20.4% to Rs 921.89 Cr in the latest annual period.
- +Debt-to-equity ratio is low at 0.06.
- +Promoter holding is significant at 63.3127% as of June 30, 2026.
- +No promoter shares are pledged, with promoter pledge at 0%.
Negatives
- −FII holding has decreased from 8.0757% in August 2021 to 2.043% in June 2026.
- −DII holding has decreased from 12.0158% in June 2022 to 9.8437% in June 2026.
- −The number of shareholders has decreased from 108818 in September 2021 to 44996 in June 2026.
- −EPS trend in quarterly results is not available, as quarterly EPS values are consistently null.
- −The latest available shareholding data is as of June 30, 2026, which is in the future relative to the current date.
Financial Performance
Windlas Biotech Limited's most recent annual revenue was Rs 921.89 Cr, representing a growth of 20.4%. The company's net profit for the latest annual period was Rs 66.456 Cr, with an EPS of Rs 32.2. Quarterly revenues have shown a generally increasing trend, from Rs 195.02 Cr in Dec 2024 to Rs 238.5 Cr in Mar 2026.
Profitability & Returns
The company's net profit margin stands at 7.35%. Return on equity (ROE) for Windlas Biotech Limited was 11.44%, and return on capital employed (ROCE) was 14.90%. The diluted EPS for the last annual period was Rs 32.2. The company's P/E ratio is 27.07.
Balance Sheet
Windlas Biotech Limited maintains a low debt-to-equity ratio of 0.06. The book value per share is Rs 281.35. The company has a dividend yield of 72% based on the provided data.
Ownership & Pledges
As of June 30, 2026, promoter holding in Windlas Biotech Limited was 63.3127%. Public shareholding was 24.8006%, while DIIs held 9.8437% and FIIs held 2.043%. The total institutional holding was 11.8867%. There are no reported promoter share pledges.
Regulatory & Surveillance
No specific regulatory or surveillance measures are reported for Windlas Biotech Limited. The company has not provided quarterly results beyond March 2026.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.